Prasad R, Yadav AS, Gorain M, et al
For each ligand, LigandScout initially identified all potential pharmacophoric features, including hydrogen bond donors/acceptors, aromatic interactions, hydrophobic regions, and charged or ionizable groups
AN2 Therapeutics (ANTX) shares plummeted 61% from $2.64 to $1.03 Friday after the company announced it would begin a strategic restructuring and terminate the Phase II and Phase III portions of the EBO-301 trial (NCT05327803) assessing epetraborole plus an optimized background regimen (OBR) in treatment-refractory MAC lung disease
Network summary of localization changes in confidently identified proteins with significant enrichment in metabolic pathways was performed as previously described [25]
For example, Meissner et al 133 conducted a randomized controlled trial evaluating lixisenatide in patients with early stage PD receiving standard treatment
Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH